
In Vivo Lenti, COGS Reduction, and the End Game Mindset with Ethan (Minaris)
In this episode of Out of the Lab, host Nicholas Crudele sits down with Eytan Abraham, President, Minaris Viral Vectors. Together, they explore the emerging wave of in vivo lentiviral vectors (LVV) and the critical operational shifts required to move from personalized ex vivo CAR-T to off-the-shelf therapies.
Ethan breaks down why traditional viral vector manufacturing faces severe yield losses during downstream purification, how early choices in cell lines and plasmids dictate final COGS, and why early-stage biotechs must begin with the "end game" in mind to ensure commercial reimbursement.
Key Topics Covered:
The In Vivo LVV Shift: Moving gene editing from outside the body (ex vivo) to inside the patient (in vivo).
Tackling Upstream & Downstream Yield Losses: How producer cell lines and purification efficiencies lower cost per patient.
The "End Game" Mindset: Why pricing, scale, and insurer reimbursement must be designed prior to Phase 1.
Selecting the Right CDMO Partner: Questions founders must ask about tech transfer track records and platform leverage.
Bridging Academic Silos: Educating PIs on translational manufacturing before locking in suboptimal processes.
More episodes from "Out of the Lab Podcast"



Don't miss an episode of “Out of the Lab Podcast” and subscribe to it in the GetPodcast app.








